Review: Bupropion and nortriptyline each increase smoking cessation rates: COMMENTARY

Prochazka, Allan V.
May 2005
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p67
Academic Journal
This article comments on the previous review on the effect of bupropion and nortriptyline on smoking cessation rates. The detailed review by previous researchers showed that only bupropion and, to a lesser extent, nortriptyline have strong evidence for effectiveness. SSRIs are not effective. All of these agents are useful for treatment of depression, which suggests that different neurochemical actions contribute to success in smoking cessation and that this success is not simply the result of treating subclinical depression. Both bupropion and nortriptyline interact with the dopamine and norepinephrine systems in the brain, whereas SSRIs do not.


Related Articles

  • Spotlight on Bupropion in Major Depressive Disorder. Dhillon, Sohita; Yang, Lily P H; Curran, Monique P // CNS Drugs;2008, Vol. 22 Issue 7, p613 

    Bupropion is presumed to be a dopamine-noradrenaline (norepinephrine) reuptake inhibitor and is an effective antidepressant. It is available as three oral formulations: (i) bupropion immediate release (IR) [Wellbutrin] administered three times daily; (ii) bupropion sustained release (SR)...

  • An overview of Teratogenic effects of venlafaxine. Sharma, Radha; Jain, Suman // International Journal of PharmTech Research;Apr2009, Vol. 1 Issue 2, p170 

    Antidepressant therapy of venlafaxine in humans believed to be associated with its inhibitory activity of 5-HT and NE re-uptake.Venlafaxine also targeted to the dopamine re-uptake recognized as a significant advance in the treatment of depression as well as in generalized anxiety disorder. The...

  • Applying neuropharmacology when treating patients with depression. Ashton, Adam Keller; D'Mello, Dale A.; Dantz, Bezalel; Hefner, Jaye; Leon, F. George; Matson, Gary A.; Montano, C. Brendan; Pradko, James F.; Sussman, Norman; Winsberg, Bertrand // Journal of Family Practice;Dec2003 Supplement, Vol. 52 Issue 12, pS34 

    Studies on the role of neurotransmitters in the effects of agents used in the treatment of depression provides increased options for clinicians. Focus is made on the new, safer classes of antidepressants, and tricyclic compounds and monoamine oxidase inhibitors are excluded from the discussion....

  • Treatment regimens for managing depression in family practice. Ashton, Adam Keller; D'Mello, Dale A.; Dantz, Bezalel; Hefner, Jaye; Leon, F. George; Matson, Gary A.; Montano, C. Brendan; Pradko, James F.; Sussman, Norman; Winsberg, Bertrand // Journal of Family Practice;Dec2003 Supplement, Vol. 52 Issue 12, pS48 

    This article presents suggestions, strategies, and practices to help clinicians manage treatment for depression into remission, monitor the remission, and prevent relapse. Clinicians should evaluate the effects of currently used antidepressants in terms of the actions of serotonin,...

  • Serotonin Reuptake Inhibitors: The Corner Stone in Treatment of Depression for Half a Century - A Medicinal Chemistry Survey. Moltzen, Ejner K.; Bang-Andersen, Benny // Current Topics in Medicinal Chemistry;Sep2006, Vol. 6 Issue 17, p1801 

    Inhibition of serotonin (5-HT) reuptake has been a central theme in the therapy of depression for half a century. Through the years these therapies have improved, particularly with regard to side effects, and today's selective serotonin reuptake inhibitors (SSRIs) constitute a reasonably...

  • Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs Millan, Mark J. // Neurotherapeutics;Jan2009, Vol. 6 Issue 1, p53 

    Summary: The past decade of efforts to find improved treatment for major depression has been dominated by genome-driven programs of rational drug discovery directed toward highly selective ligands for nonmonoaminergic agents. Selective drugs may prove beneficial for specific symptoms, for...

  • Abnormal temporal difference reward-learning signals in major depression. P. Kumar; G. Waiter; T. Ahearn; M. Milders; I. Reid; J. D. Steele // Brain: A Journal of Neurology;Aug2008, Vol. 131 Issue 8, p2084 

    Anhedonia is a core symptom of major depressive disorder (MDD), long thought to be associated with reduced dopaminergic function. However, most antidepressants do not act directly on the dopamine system and all antidepressants have a delayed full therapeutic effect. Recently, it has been...

  • Treating Tobacco Addiction – Nicotine or No Nicotine? Benowitz, Neal L. // New England Journal of Medicine;10/23/97, Vol. 337 Issue 17, p1230 

    The author discusses medical research that has found that using anti-depressant medications significantly increases the likelihood of maintaining a smoking cessation program. Nicotine has been the mainstay of pharmacotherapy for tobacco addiction, but other medications, such as the...

  • Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. Furukawa, Toshi A; Akechi, Tatsuo; Shimodera, Shinji; Yamada, Mitsuhiko; Miki, Kazuhira; Watanabe, Norio; Inagaki, Masatoshi; Yonemoto, Naohiro // Trials;2011, Vol. 12 Issue 1, p116 

    Background: After more than half a century of modern psychopharmacology, with billions of dollars spent on antidepressants annually world-wide, we lack good evidence to guide our everyday decisions in conducting antidepressant treatment of patients with major depression. First we...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics